Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
Caribou Biosciences (CRBU) Stock Price & Analysis
512 Followers
CRBU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.44 - $8.59
Previous Close$3.5
Volume1.09M
Average Volume (3M)1.65M
Market Cap
$316.11M
Enterprise Value$14.39M
Total Cash (Recent Filing)$328.83M
Total Debt (Recent Filing)$27.11M
Price to Earnings (P/E)-2.4
Beta1.94
Next Earnings
Aug 06, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding90,314,501
10 Day Avg. Volume1,674,720
30 Day Avg. Volume1,645,239
Standard Deviation0.29
R-Squared0.23
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.91
Price to Sales (P/S)9.17
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.42
Enterprise Value/Gross Profit0.42
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$22.50Price Target Upside514.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Caribou Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCRBU received IND clearance for its allogeneic anti-CD19 CAR-T for the treatment of lupus nephritis and extrarenal lupus, potentially offering advantages over existing treatments.
Financial HealthCaribou ended the year with a strong cash position expected to provide an operational runway into the first quarter of 2026, ensuring the company's stability and continued research.
Stock RatingAnalyst maintains a 'Buy' rating on Caribou with a price objective of 17.00 USD, reflecting optimism about the company's prospects and potential market performance.
Bears Say
Clinical Trial DelaysDelay in the Ph3 LBCL trial start to generate a significant selloff.
Drug Efficacy And SafetyLimited data on long-term efficacy and concerns about the risk of secondary malignancies with CAR Ts have caused some pause.
Therapeutic DevelopmentCRBU paused development of CB-020, its preclinical allogeneic anti-ROR1 CAR-NK cell therapy.
---
Ownership Overview
8.74% Insiders
9.27% Mutual Funds
19.20% Other Institutional Investors
62.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $3.44 and its highest was $8.59 in the past 12 months.
What is Caribou Biosciences’s market cap?
Currently, no data Available
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Aug 06, 2024 which is in 89 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on May 07, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.411 by -$0.049.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -$0.45.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 90,317,770 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.411. Following the earnings report the stock price went down -6.166%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Among the largest hedge funds holding Caribou Biosciences’s share is Woodline Partners LP. It holds Caribou Biosciences’s shares valued at 7M.
---
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (514.75% Upside)
$22.50 (514.75% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.60%
12-Months-Change
Fundamentals
Return on Equity
-37.09%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
---
CRBU Stock 12 Month Forecast
Average Price Target
$22.50
▲(514.75% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Best Analysts Covering CRBU
1 Year
1 Year Success Rate
2/19 ratings generated profit
1 Year Average Return
-26.98%
reiterated a buy rating last month
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 10.53% of your transactions generating a profit, with an average return of -26.98% per trade.
---